Pharmacogenomics and Effective Treatment With Clopidogrel

Completed

• Conditions: Pharmacogenomics and Cardiovascular Events
• Interventions: Genetic: Pharmacogenomics

• Registration Number: NCT01611545
• Lead Sponsor: Avera McKennan Hospital & University Health Center

Brief Summary

The aim of this biospecimen repository is to evaluate an individual's genotype, identify the variances, and understand how they relate to treatment with clopidogrel.

Detailed Description

The objective of this project is to distinguish genetic profiles that will assist a practitioner in determining the right dose or alternate medication for the patient. In partnership with the genetics team of the Avera Institute for Human Genetics and physicians with the Avera Heart Hospital of South Dakota and North Central Heart Institute, the research team will perform genetic analysis to identify genetic variances.

Study Timeline

• Study First Submitted: 2012-05-31
• Study Start: 2012-06
• Study First Submitted QC: 2012-06-04
• Study First Posted: 2012-06-05
• Primary Completion: 2015-01
• Study Completion: 2015-01
• Status Verified: 2015-06
• Last Update Submitted: 2015-06-09
• Last Update Posted: 2015-06-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

• Currently taking or prescribed Clopidogrel or under consideration
• Acute/interventionPatients of the Avera Heart Hospital
• Cardiology clinic patients with the Avera Heart Hospital and North Central Heart Institute

Exclusion Criteria

• Unable to provide informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Clopidogrel	Pharmacogenomics	Patients taking or prescribed clopidogrel or under consideration Utilizing pharmacogenomics to determine the most effective treatment

Trial Locations

Locations (1)

Avera Institute for Human Genetics; 🇺🇸 Sioux Falls, South Dakota, United States